Back to results
US 2026/0224629 A1Published application
Armored immunoresponsive cells targeting dll3 and uses thereof
AssigneesMemorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases
InventorRenier J. BRENTJENS
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target DLL3 and cells comprising such DLL3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the DLL3-targeted antigen-recognizing receptors for treatment.
Claims20
A cell comprising
- a) an antigen-recognizing receptor comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain;
- b) an exogenous IL-18 polypeptide;
- wherein the extracellular antigen-binding domain specifically binds to DLL3, wherein the extracellular antigen-binding domain comprises:
- i) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 1, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 2, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 3;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 4, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 6;
- ii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 11, a CDR2 comprising an amino acid sequence set forth in SEQ ID NO:
- 12, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 13;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 14, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 15, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 16;
- iii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 21, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 22, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 23;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 24, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 25, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 26;
- iv) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 11, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 31, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 32;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 25, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 33, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 34;
- v) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 39, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 40, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 41, and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 42, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 43, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 44;
- vi) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 49, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 50, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 51;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 52, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 53, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 54;
- vii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 59, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 60, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 61;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 62, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 63, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 64;
- or
- viii) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 69, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 70, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 71;
- and a light chain variable region comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 62, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 72, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 73.
64 more elements
Dependencies are inferred from the claim text.